SPOP Antibody (YA2054)

Speckle-type POZ protein (SPOP) functions as an E3 ubiquitin ligase adaptor that mediates substrate-specific ubiquitination and proteasomal degradation^[1]. Mechanistically, SPOP targets proteins such as FADD and GLI3, regulating NF-κB and Sonic hedgehog (SHH) signaling pathways, respectively, which influence cancer cell proliferation and migration^[2][3]. In hepatoblastoma, SPOP acts as a tumor suppressor by modulating SLC7A1 stability and arginine metabolism through the PI3K/Akt pathway^[4]. The MATH domain of SPOP is critical for recognizing diverse substrates, facilitating the orchestration of multiple cellular processes and maintaining protein homeostasis^[1]. Compared with related isoforms or mutants, SPOP exhibits substrate specificity that determines differential signaling outcomes in various disease contexts^[2][3]. Small molecules targeting post-translational modification (PTM) isoforms of SPOP and other ubiquitin ligases provide opportunities for isoform-selective modulation and precision therapeutic design^[5]. In experimental applications, SPOP overexpression reduces tumor growth, induces apoptosis, and modulates immune signaling, highlighting its utility as a functional biomarker and therapeutic target in cancer research^[6]. These findings collectively emphasize the biological relevance of SPOP in regulating protein degradation, isoform-specific pathway modulation, and its potential exploitation in experimental and therapeutic strategies^{[2][4][6][1][3][5]}.